FDA has delayed implementation of proposed changes to its definition of “intended use” by one year in the face of significant stakeholder protest.
A final rule published Jan. 9 would have broadened the definition of “intended use” to what is called the “totality of evidence” standard, meaning manufacturers could be held responsible if...